Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : GZTC -- Ignore unavailable to you. Want to Upgrade?

To: kinkblot who wrote (612)	9/16/1999 4:40:00 PM
From: kinkblot	Read Replies (2) \| Respond to of 752

Announcements wrt previously undisclosed antiangiogenic compound aaATIII: Preclinical study published in today's issue of Science cites potency of aaATIII genzyme.com Genzyme Molecular Oncology and the ATIII LLC agree to develop aaATIII genzyme.com Over the next few months, Genzyme will conduct studies to replicate the work of Dr. Folkman's laboratory, conduct other preclinical studies, and scale-up production of the protein. Because of the LLC's experience producing ATIII transgenically, ample quantities of aaATIII are expected to be available for use in development efforts. aaATIII is already being produced for preclinical studies and the ATIII LLC supplied aaATIII to Dr. Folkman's laboratory for some of the preclinical studies detailed in the Science publication.